Didier Blaise

Didier Blaise

Auto-generated profile, based on publicly available information

Didier Blaise

Departement D’Hematologie, Programme de Transplantation et de Therapie Cellulaire, Centre de Recherche en Cancerologie de Marseille, Institut Paoli Calmettes, Marseille, France

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2020 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
ASAlexandros Spyridonidis
Alexandros Spyridonidis
MLMyriam Labopin
Myriam Labopin
BSBipin N. Savani
Bipin N. Savani
RNRiitta Niittyvuopio
Riitta Niittyvuopio
DBDidier Blaise
Didier Blaise
MMMohamad Mohty
Mohamad Mohty

12 September 2019 in Blood
Verified
Journal Article
Closed access
PDF file
GBGiorgia Battipaglia
Giorgia Battipaglia
MLMyriam Labopin
Myriam Labopin
NKNicolaus Kröger
Nicolaus Kröger
AVAntonin Vitek
Antonin Vitek
BABoris Afanasyev
Boris Afanasyev
MMMohamad Mohty
Mohamad Mohty
The use of anti-thymocyte globulin (ATG) has represented the standard of care in graft-versus-host disease (GVHD) prophylaxis in patients undergoing a mismatched unrelated donor (MMUD) transplant. The safety and feasibility of posttransplant cyclophosphamide (PTCY) in this setting have been reported recently, but no study has compared the outcomes of PTCY vs ATG in 9/10 MMUD transplants. Using the registry data of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation, we performed a matched-pair analysis comparing those 2 strategies in a 9/10 MMUD setting. Ninety-three patients receiving PTCY were matched with 179 patients receiving ATG. A significantly lower incidence of severe acute GVHD was observed with PTCY compared with ATG. Recipients of the former also showed higher leukemia-free survival and GVHD/relapse-free survival (GRFS). When performing a subgroup analysis including patients receiving peripheral blood stem cells, being in complete remission, or receiving the same associated immunosuppressive agents, superiority of PTCY over ATG was confirmed. Similar to the haploidentical setting, use of PTCY is an effective anti-GVHD prophylaxis in the 9/10 MMUD transplant. Use of PTCY may also provide better outcomes in long-term disease control. These results need confirmation in large prospective randomized trials.

30 May 2023 in Cancer Discovery
Verified
Journal Article
Open access
MDMichael J. Dickinson
Michael J. Dickinson
PBPere Barba
Pere Barba
UJUlrich Jäger
Ulrich Jäger
NSNirav N Shah
Nirav N Shah
DBDidier Blaise
Didier Blaise
IFIan W. Flinn
Ian W. Flinn
CAR T-cell product quality and stemness (Tstem) are major determinants of in vivo expansion, efficacy, and clinical response. Prolonged ex vivo culturing is known to deplete Tstem, affecting clinical outcome. YTB323, a novel autologous CD19-directed CAR T-cell therapy expressing the same validated CAR as tisagenlecleucel, is manufactured using a next-generation platform in <2 days. Here, we report the preclinical development and preliminary clinical data of YTB323 in adults with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL; NCT03960840). In preclinical mouse models, YTB323 exhibited enhanced in vivo expansion and antitumor activity at lower doses than traditionally manufactured CAR T cells. Clinically, at doses 25-fold lower than tisagenlecleucel, YTB323 showed (i) promising overall safety [cytokine release syndrome (any grade, 35%; grade ≥3, 6%), neurotoxicity (any grade, 25%; grade ≥3, 6%)]; (ii) overall response rates of 75% and 80% for DL1 and DL2, respectively; (iii) comparable CAR T-cell expansion; and (iv) preservation of T-cell phenotype. Current data support the continued development of YTB323 for r/r DLBCL. Significance: Traditional CAR T-cell manufacturing requires extended ex vivo cell culture, reducing naive and stem cell memory T-cell populations and diminishing antitumor activity. YTB323, which expresses the same validated CAR as tisagenlecleucel, can be manufactured in <2 days while retaining T-cell stemness and enhancing clinical activity at a 25-fold lower dose. See related commentary by Wang, p. 1961. This article is featured in Selected Articles from This Issue, p. 1949

4 March 2019 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
SCStefan Ciurea
Stefan Ciurea
MMMonzr M. Al Malki
Monzr M. Al Malki
PKPiyanuch Kongtim
Piyanuch Kongtim
EFEphraim J. Fuchs
Ephraim J. Fuchs
LLLeo Luznik
Leo Luznik
ANArnon Nagler
Arnon Nagler

24 April 2023 in Bone Marrow Transplantation
Verified
Journal Article
Open access
PDF file
MMMohamad Mohty
Mohamad Mohty
FMFlorent Malard
Florent Malard
AAAhmed S. Alaskar
Ahmed S. Alaskar
MAMahmood Aljurf
Mahmood Aljurf
MAMutlu Arat
Mutlu Arat
ECEnric Carreras
Enric Carreras
Sinusoidal obstruction syndrome, also known as veno-occlusive disease (SOS/VOD), is a potentially life-threatening complication that can develop after hematopoietic cell transplantation (HCT). A new definition for diagnosis, and a severity grading system for SOS/VOD in adult patients, was reported a few years ago on behalf of the European Society for Blood and Marrow Transplantation (EBMT). The aim of this work is to update knowledge regarding diagnosis and severity assessment of SOS/VOD in adult patients, and also its pathophysiology and treatment. In particular, we now propose to refine the previous classification and distinguish probable, clinical and proven SOS/VOD at diagnosis. We also provide an accurate definition of multiorgan dysfunction (MOD) for SOS/VOD severity grading based on Sequential Organ Failure Assessment (SOFA) score.

23 December 2019 in Blood Advances
Verified
Journal Article
Open access
PDF file
Francine Garnache OttouFrancine Garnache Ottou
Francine Garnache Ottou
CVChrystelle Vidal
Chrystelle Vidal
SBSabeha Biichlé
Sabeha Biichlé
FRFlorian Renosi
Florian Renosi
EPEve Poret
Eve Poret
EDEric Deconinck
Eric Deconinck
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia for which we developed a nationwide network to collect data from new cases diagnosed in France. In a retrospective, observational study of 86 patients (2000-2013), we described clinical and biological data focusing on morphologies and immunophenotype. We found expression of markers associated with plasmacytoid dendritic cell origin (HLA-DRhigh, CD303+, CD304+, and cTCL1+) plus CD4 and CD56 and frequent expression of isolated markers from the myeloid, B-, and T-lymphoid lineages, whereas specific markers (myeloperoxidase, CD14, cCD3, CD19, and cCD22) were not expressed. Fifty-one percent of cytogenetic abnormalities impact chromosomes 13, 12, 9, and 15. Myelemia was associated with an adverse prognosis. We categorized chemotherapeutic regimens into 5 groups: acute myeloid leukemia (AML)–like, acute lymphoid leukemia (ALL)–like, lymphoma (cyclophosphamide, doxorubicin, vincristine, and prednisone [CHOP])–like, high-dose methotrexate with asparaginase (Aspa-MTX) chemotherapies, and not otherwise specified (NOS) treatments. Thirty patients received allogeneic hematopoietic cell transplantation (allo-HCT), and 4 patients received autologous hematopoietic cell transplantation. There was no difference in survival between patients receiving AML-like, ALL-like, or Aspa-MTX regimens; survival was longer in patients who received AML-like, ALL-like, or Aspa-MTX regimens than in those who received CHOP-like regimens or NOS. Eleven patients are in persistent complete remission after allo-HCT with a median survival of 49 months vs 8 for other patients. Our series confirms a high response rate with a lower toxicity profile with the Aspa-MTX regimen, offering the best chance of access to hematopoietic cell transplantation and a possible cure.